Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Breath LS is a combination respiratory medication manufactured by Kaiser Pharmaceutical, primarily available in India. It contains three active ingredients: levosalbutamol, a selective beta-2 adrenergic receptor agonist that promotes bronchodilation; ambroxol, a mucolytic agent that thins and loosens mucus; and guaifenesin, an expectorant that increases the volume of respiratory tract secretions to facilitate their removal. The drug is formulated as an oral syrup and drops, and it is indicated for the treatment of productive cough associated with conditions such as bronchitis, bronchial asthma, and emphysema.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Breath LS.